Cabozantinib malateProduct ingredient for Cabozantinib

Name
Cabozantinib malate
Drug Entry
Cabozantinib

Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.6 In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.7,8

Accession Number
DBSALT001762
Structure
Synonyms
cabozantinib (S)-malate / cabozantinib L-malate / cabozantinib s-malate
UNII
DR7ST46X58
CAS Number
1140909-48-3
Weight
Average: 635.601
Monoisotopic: 635.191522341
Chemical Formula
C32H30FN3O10
InChI Key
HFCFMRYTXDINDK-WNQIDUERSA-N
InChI
InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
IUPAC Name
(2S)-2-hydroxybutanedioic acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
SMILES
O[C@@H](CC(O)=O)C(O)=O.COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2
KEGG Drug
D10095
ChemSpider
25948203
ChEBI
72319
ChEMBL
CHEMBL2103868
Predicted Properties
PropertyValueSource
Water Solubility0.00199 mg/mLALOGPS
logP4.01ALOGPS
logP4.66Chemaxon
logS-5.4ALOGPS
pKa (Strongest Acidic)13.46Chemaxon
pKa (Strongest Basic)5.9Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area98.78 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity136.12 m3·mol-1Chemaxon
Polarizability51.49 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon